Cash Flow Statement (Annual)
HUM / Humana, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||1,040,000||1,099,000||1,419,000||1,222,000||1,231,000||1,147,000||1,276,000||614,000||2,448,000|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Available For Sale Securities Gross Realized Gain Loss Net||20,000||6,000||11,000||33,000||22,000||20,000||146,000||96,000||14,000|
|Share Based Compensation||66,000||63,000||67,000||82,000||92,000||98,000||109,000||115,000||157,000|
|Depreciation And Amortization||250,000||263,000||303,000||338,000||426,000||449,000||354,000||388,000||410,000|
|Amortization Of Intangible Assets||37,000||38,000||54,000||75,000||117,000||121,000||93,000||77,000||75,000|
|Increase Decrease In Deferred Income Taxes||27,000||199,000||-22,000||80,000||-42,000||64,000||2,000||71,000||-132,000|
|Increase Decrease In Operating Capital|
|Increase Decrease In Receivables||60,000||46,000||106,000||-326,000||251,000||264,000||180,000||158,000||-406,000|
|Increase Decrease In Other Operating Assets||-113,000||-81,000||183,000||253,000||330,000||952,000||872,000||-426,000||582,000|
|Increase Decrease In Health Care Insurance Liabilities||17,000||247,000||256,000||-41,000||109,000||582,000||501,000||-413,000||105,000|
|Increase Decrease In Other Operating Liabilities||14,000||722,000||194,000||300,000||313,000||413,000||-129,000||937,000||641,000|
|Increase Decrease In Deferred Revenue||-9,000||-46,000||26,000||-43,000||-24,000||155,000||3,000||-84,000||98,000|
|Increase Decrease In Other Operating Capital Net||-19,000||-45,000||-61,000||-79,000||-93,000||-42,000||-70,000||-162,000||-155,000|
|Net Cash Provided By Used In Operating Activities||1,422,000||2,242,000||2,079,000||1,923,000||1,716,000||1,618,000||868,000||1,936,000||4,051,000|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Businesses Net Of Cash Acquired||12,000||833,000||226,000||1,235,000||187,000||18,000||38,000||7,000||31,000|
|Payments To Acquire Property Plant And Equipment||185,000||222,000||346,000||410,000||441,000||528,000||523,000||527,000||526,000|
|Payments To Acquire Available For Sale Securities Debt||7,197,000||4,589,000||3,678,000||3,221,000||3,261,000||2,883,000||6,739,000||6,566,000||6,265,000|
|Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities||1,271,000||1,821,000||1,569,000||1,497,000||1,077,000||885,000||1,065,000||1,426,000||1,111,000|
|Proceeds From Sale Of Available For Sale Securities Debt||3,951,000||2,012,000||1,259,000||1,404,000||1,592,000||2,409,000||5,493,000||4,312,000||2,768,000|
|Net Cash Provided By Used In Investing Activities||-1,859,000||-1,811,000||-1,358,000||-1,965,000||-1,182,000||-63,000||320,000||-1,362,000||-2,941,000|
|Net Cash Provided By Used In Financing Activities|
|Increase Decrease In Other Deposits||-||-237,000||-378,000||-397,000||-150,000||-919,000||-296,000||1,093,000||1,823,000|
|Proceeds From Issuance Of Senior Long Term Debt||-||0||0||990,000||0||1,733,000||0||0||1,779,000|
|Proceeds From Repayments Of Commercial Paper||-||-||-||-||-||0||298,000||-2,000||-153,000|
|Increase Decrease In Book Overdrafts||150,000||35,000||-103,000||18,000||79,000||-69,000||-33,000||-89,000||-71,000|
|Payments For Repurchase Of Common Stock||23,000||108,000||541,000||518,000||531,000||872,000||385,000||104,000||3,365,000|
|Payments Of Dividends||0||0||82,000||165,000||168,000||172,000||172,000||177,000||220,000|
|Proceeds From Stock Options Exercised||17,000||-63,000||128,000||57,000||60,000||29,000||23,000||14,000||63,000|
|Net Cash Provided By Used In Financing Activities||80,000||-371,000||-1,017,000||-29,000||-702,000||-758,000||-552,000||732,000||-945,000|
|Cash And Cash Equivalents Period Increase Decrease||-357,000||60,000||-296,000||-71,000||-168,000||797,000||636,000||1,306,000||165,000|
|Cash And Cash Equivalents At Carrying Value||-||-||1,377,000||1,306,000||1,138,000||1,935,000||2,571,000||3,877,000||4,042,000|
|Supplemental Cash Flow Information|
|Income Taxes Paid Net||627,000||785,000||874,000||745,000||734,000||1,030,000||1,179,000||916,000||1,498,000|
Peers - Hospital and Medical Service Plans (6324)
ANTM / Anthem, Inc.
ANTX / Anthem, Inc., 5.25% Equity Units due 5/1/2018
ATHTF / Anthem United, Inc.
CHCR / Comprehensive Care Corp.
CI / Cigna Corp.
CNC / Centene Corp.
7h - Asif
History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
as of ET